Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up to 8-fold change (6 mg/kg) in total bile acids in serum, exceeding the
… ProQR Announces Closing of Underwritten Public Offering of … share. All of the shares are being offered by ProQR. The closing included the full exercise of the … securities laws of any such state or jurisdiction. About ProQRProQR Therapeutics is dedicated to changing lives …